Cox P H, Verweij J, Pillay M, Stoter G, Schonfeld D
Department of Nuclear Medicine, Dr. Daniel den Hoed Cancer Institute, Rotterdam, The Netherlands.
Eur J Nucl Med. 1988;14(1):50-2. doi: 10.1007/BF00252619.
111In-antimyosin monoclonal antibody complex passes through damaged myocardial cell membranes and binds to the intracellular myosin. Normal myocardial and other muscle cells show no uptake. Rhabdomyosarcoma and Leiomyosarcoma cells also contain intracellular myosin and the cell membrane permeability is greater than normal. Significant uptake of 111In-antimyosin was observed in patients with Leiomyosarcoma and Rhabdomyosarcoma suggesting that the reagent has a potential for the in vivo detection of these tumour types. Tumour to background ratios of 10:1 were measured in one case and in view of the fact that the site of accumulation is intracellular, antimyosin may have a potential as a carrier for therapeutic agents.
铟-111抗肌球蛋白单克隆抗体复合物穿过受损的心肌细胞膜并与细胞内的肌球蛋白结合。正常心肌细胞和其他肌肉细胞无摄取。横纹肌肉瘤和平滑肌肉瘤细胞也含有细胞内肌球蛋白,且细胞膜通透性高于正常细胞。在平滑肌肉瘤和横纹肌肉瘤患者中观察到铟-111抗肌球蛋白有显著摄取,提示该试剂有在体内检测这些肿瘤类型的潜力。在一例患者中测得肿瘤与本底比值为10:1,鉴于积累部位在细胞内,抗肌球蛋白可能有作为治疗药物载体的潜力。